IGF1R

Purple Biotech Reports First Quarter 2024 Financial Results

Retrieved on: 
Tuesday, May 21, 2024
Net, Risk, Tumor microenvironment, SCCHN, FDA, Pancreatic cancer, CA19-9, Oncology, Randomness, NK, Escape Room, Recurrence, AACR, Cancer, STAT3, Table, B cell, Administration, Phase II, PDAC, Average cost, Neoplasm, Safety, Jefferies Group, NSCLC, ADS, Interim, ASCO, Poster, International, Society, Drug resistance, SAB, IGF1R, Nivolumab, Cetuximab, DCR, Patient, Quarter, Pharmacodynamics, Death, Efficacy, CM24, Biomarker, SOC, Annual general meeting, Pharmaceutical industry

REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024.

Key Points: 
  • REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024.
  • Financial Results for the Quarter Ended March 31, 2024
    Research and Development Expenses were $3.4 million for the three months ended March 31, 2024, a decrease of $0.1 million, or 2.8%, compared to $3.5 million in the same period of 2023.
  • As of March 31, 2024, Purple Biotech had cash and cash equivalents and short-term deposits of $10.8 million.
  • A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
Online, Cancer, Research, Lung cancer, IRS, Head, CSC, Tumor microenvironment, Biomarker, Abstract, AACR, Publication, Neoplasm, IGF1R, Drug resistance, Recurrence, STAT3, Escape Room, Neck, Pharmaceutical industry

REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting which takes place April 5-11, 2024, in San Diego, California.

Key Points: 
  • “The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers.
  • These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219’s attributes,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
  • “We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.”
    Dr Hadas Reuveni, VP Research and Development at Purple Biotech, added, “At AACR 2024 we will present new data related to NT219.
  • The presented posters will be available on the Publications section of Purple Biotech’s website, following their presentations at the conference.

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Society for Immunotherapy of Cancer, Trial of the century, Biomarker, Biotechnology, Regeneron Pharmaceuticals, ZAP70, Hotspot, Protein, IGF1R, SITC, Immunotherapy, Clinical trial, Biology, Annual general meeting, Casitas, Therapy, Patient, Pharmaceutical industry

BOSTON, Nov. 3, 2023 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced the presentation of additional preclinical data from the Company's Casitas B-lineage lymphoma proto-oncogene (CBL-B) program in a poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • BOSTON, Nov. 3, 2023 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced the presentation of additional preclinical data from the Company's Casitas B-lineage lymphoma proto-oncogene (CBL-B) program in a poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • "Our enthusiasm for the therapeutic potential of HST-1011, a potential best-in-class CBL-B inhibitor, is partly driven by our belief that it can drive single-agent biological activity," said Timothy Reilly, Ph.D., Chief Development Officer of HotSpot.
  • The presentation describes preclinical data in which HotSpot CBL-B inhibitors were evaluated in both in vitro and in vivo settings to identify and then characterize a repertoire of potential proximal biomarkers of CBL-B inhibitory activity.
  • Several proteins, including phosphorylated ZAP70, Notch1 and IGF1R, showed robust dose-dependent effects and were further assessed for their reliability and potential feasibility for use in a clinical setting.

Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product

Retrieved on: 
Wednesday, June 15, 2022
IGF1R, Derma, Tumor microenvironment, Laboratoires Pierre Fabre, Marketing, Patient, CGMP, Melanoma, Breast, Fine chemical, Vaccine, Pharmaceutical industry

Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered by Pierre Fabre targeting solid tumors, from its fill and finish facility in Stein, Switzerland

Key Points: 
  • Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered by Pierre Fabre targeting solid tumors, from its fill and finish facility in Stein, Switzerland
    TOULOUSE, France, June 15, 2022 /PRNewswire/ --Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre announced today that the companies have entered into a manufacturing agreement.
  • Lonza will provide cGMP drug product (DP) manufacturing services for clinical supply from its fill and finish facility at Stein, Switzerland.
  • Jean-Luc Lowinski, Pierre Fabre Medical Care CEO, said: "We are delighted to entrust the production of the W0180 Drug Product to Lonza.
  • Its portfolio includes several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avne, Klorane, Ducray, Ren Furterer, A-Derma and Pierre Fabre Oral Care.

Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product

Retrieved on: 
Wednesday, June 15, 2022
IGF1R, Derma, Tumor microenvironment, Laboratoires Pierre Fabre, Marketing, Patient, CGMP, Melanoma, Breast, Fine chemical, Vaccine, Pharmaceutical industry

Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered by Pierre Fabre targeting solid tumors, from its fill and finish facility in Stein, Switzerland

Key Points: 
  • Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered by Pierre Fabre targeting solid tumors, from its fill and finish facility in Stein, Switzerland
    TOULOUSE, France, June 15, 2022 /PRNewswire/ --Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre announced today that the companies have entered into a manufacturing agreement.
  • Lonza will provide cGMP drug product (DP) manufacturing services for clinical supply from its fill and finish facility at Stein, Switzerland.
  • Jean-Luc Lowinski, Pierre Fabre Medical Care CEO, said: "We are delighted to entrust the production of the W0180 Drug Product to Lonza.
  • Its portfolio includes several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avne, Klorane, Ducray, Ren Furterer, A-Derma and Pierre Fabre Oral Care.

ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

Retrieved on: 
Wednesday, January 12, 2022
Neurodegeneration, ABL, Technology, Patient, Bispecific monoclonal antibody, Cerebrospinal fluid, Central nervous system, CNS, Parkinson's disease, CSF, Safety, Achievement, CEO, Synucleinopathy, KOSDAQ, HSR, Traffic barrier, BBB, Doctor of Philosophy, Therapy, Alpha-synuclein, Alzheimer's disease, Lists of diseases, IGF1R, Brain, Partnership, Parkinson, Vaccine, Pharmaceutical industry

ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized.

Key Points: 
  • ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized.
  • Thereafter, SANOFI will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide.
  • Utilizing Grabody-B technology, ABL301 effectively carries the anti-alpha-synuclein antibody across the BBB to enhance therapeutic efficacy against Parkinson's disease.
  • It is being developed as a potential first-in-class bispecific antibody therapeutics for the treatment of synucleinopathies, including Parkinson's disease.

ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

Retrieved on: 
Tuesday, January 11, 2022
Neurodegeneration, ABL, Technology, Patient, Bispecific monoclonal antibody, Cerebrospinal fluid, Central nervous system, CNS, Parkinson's disease, CSF, Safety, Achievement, CEO, Synucleinopathy, KOSDAQ, HSR, View, Traffic barrier, BBB, Doctor of Philosophy, Therapy, Multimedia, Alpha-synuclein, Alzheimer's disease, Lists of diseases, IGF1R, Brain, Partnership, Parkinson, Vaccine, Pharmaceutical industry

ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized.

Key Points: 
  • ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized.
  • Meanwhile, ABL will lead the preclinical development and Phase 1 clinical trial of ABL301.
  • Thereafter, SANOFI will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide.
  • Utilizing Grabody-B technology, ABL301 effectively carries the anti-alpha-synuclein antibody across the BBB to enhance therapeutic efficacy against Parkinson's disease.

AstaReal and University of Tsukuba, Japan awarded Patent on Astaxanthin and Exercise Therapy for Improving Cognitive Function

Retrieved on: 
Wednesday, December 1, 2021
Fibroblast growth factor receptor, Astar Air Cargo, AHN, News, Neuron, Tonian, Insulin, CEO, Katagiri, Brain, Multi-system (rail), Growth factor, Exercise, Memory, Physical therapy, Gene expression, Bureau of Oceans and International Environmental and Scientific Affairs, Blood, University, Cognition, Mouse, Hippocampus, Neurogenesis, View, Research, Adult, Patent, Yook, Learning, University of Tsukuba, IGF1R, Multimedia, Life, Gene, Spatial memory, Quality of life, Toy, Online shopping

AstaReal astaxanthin modulates genes in the brain that are involved in learning, memory and neuron formation.

Key Points: 
  • AstaReal astaxanthin modulates genes in the brain that are involved in learning, memory and neuron formation.
  • Exercise therapy has been shown to stimulate AHN, as well as enhance and help maintain cognitive function.
  • This new patent from AstaReal ( US 11,116732 ) shows that astaxanthin combined with exercise can improve the effects of exercise on AHN, learning, and spatial memory by modulating genetic expression in the hippocampus.
  • Pre -clinical studies led by Prof Hideaki Soya at the University of Tsukuba, showed Astaxanthin combined with exercise improved cognitive function better than either exercise or astaxanthin treatments alone.